



Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

February 11, 2026

DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET.

Information on how to participate is as follows.

Access to the live call:

Via telephone: Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 675507

Via online: A webcast of the call will be available on the Investor Relations section of the Company's website at www.amarincorp.com.

Access to the replay:

Via telephone: Dial in within the United States: 877-481-4010

International dial in: 919-882-2331

Access Code: 53567

Via online: A replay of the webcast will be accessible through the Investor Relations section of the Company's website at www.amarincorp.com, beginning shortly after the end of the live call and available until 8/25/26.

About Amarin

Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world's leading cause of death, CVD.

Availability of Other Information About Amarin

Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (<http://www.amarincorp.com/investor-relations>), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin's investor relations website and may include social media channels. The contents of Amarin's website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Media Inquiries:

Tegan Berry

Amarin Corporation plc

PR@amarincorp.com

Investor Inquiries:

Devin Sullivan & Conor Rodriguez

The Equity Group on Behalf of Amarin

dsullivan@theequitygroup.com or crodriguez@theequitygroup.com

Investor.relations@amarincorp.com